These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38340111)

  • 1. Combination of Acute and Maintenance Esketamine Treatment With Adjunctive Long-Term Vagus Nerve Stimulation in Difficult-to-Treat Depression.
    Kavakbasi E; Baune BT
    Neuromodulation; 2024 Jun; 27(4):766-773. PubMed ID: 38340111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments.
    Kavakbasi E; Bauermeister H; Lemcke L; Baune BT
    Brain Sci; 2024 Feb; 14(2):. PubMed ID: 38391733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vagus nerve stimulation as adjunctive therapy in patients with difficult-to-treat depression (RESTORE-LIFE): study protocol design and rationale of a real-world post-market study.
    Young AH; Juruena MF; De Zwaef R; Demyttenaere K
    BMC Psychiatry; 2020 Sep; 20(1):471. PubMed ID: 32993573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid titration protocol - Experiences with a dynamic novel titration regime for vagus nerve stimulation in a group of depressive patients.
    Moeller S; Wang R; Aydin M; Lam AP; Sitter A; Grüter J; Philipsen A; Müller HHO
    J Clin Neurosci; 2020 Apr; 74():262-264. PubMed ID: 31447363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression.
    Conway CR; Kumar A; Xiong W; Bunker M; Aaronson ST; Rush AJ
    J Clin Psychiatry; 2018 Aug; 79(5):. PubMed ID: 30152645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality.
    Aaronson ST; Sears P; Ruvuna F; Bunker M; Conway CR; Dougherty DD; Reimherr FW; Schwartz TL; Zajecka JM
    Am J Psychiatry; 2017 Jul; 174(7):640-648. PubMed ID: 28359201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
    Santucci MC; Ansari M; Nikayin S; Radhakrishnan R; Rhee TG; Wilkinson ST
    J Clin Psychiatry; 2024 Oct; 85(4):. PubMed ID: 39361411
    [No Abstract]   [Full Text] [Related]  

  • 11. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
    Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry.
    McAllister-Williams RH; Sousa S; Kumar A; Greco T; Bunker MT; Aaronson ST; Conway CR; Rush AJ
    Int J Bipolar Disord; 2020 May; 8(1):13. PubMed ID: 32358769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vagus Nerve Stimulation as an Alternative to Maintenance Electroconvulsive Therapy for Difficult-to-Treat Depression.
    Migchels C; Obbels J; McAllister-Williams H; Demyttenaere K; Sienaert P
    J ECT; 2024 Sep; 40(3):213-215. PubMed ID: 38373170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1 year.
    Cristancho P; Cristancho MA; Baltuch GH; Thase ME; O'Reardon JP
    J Clin Psychiatry; 2011 Oct; 72(10):1376-82. PubMed ID: 21295002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Sustained Cognitive Benefits of Vagus Nerve Stimulation in Refractory Depression.
    Desbeaumes Jodoin V; Richer F; Miron JP; Fournier-Gosselin MP; Lespérance P
    J ECT; 2018 Dec; 34(4):283-290. PubMed ID: 29870432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting Up a Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression.
    Kraus C; Quach D; Sholtes DM; Kavakbasi E; De Zwaef R; Dibué M; Zajecka J; Baune BT
    Neuromodulation; 2022 Apr; 25(3):316-326. PubMed ID: 35123881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vagus nerve stimulation allows to cease maintenance electroconvulsive therapy in treatment-resistant depression: a retrospective monocentric case series.
    Aboubakr O; Domenech P; Heurtebise I; Gaillard R; Guy-Rubin A; Carron R; Duriez P; Gorwood P; Vinckier F; Pallud J; Zanello M
    Front Psychiatry; 2023; 14():1305603. PubMed ID: 38352166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics of a European patient population with difficult-to-treat depression (RESTORE-LIFE) treated with adjunctive vagus nerve stimulation.
    Demyttenaere K; Costa T; Kavakbasi E; Jiang M; Scheltens A; Dibué M; Hall BE; Andrade P; McAllister-Williams RH; Baune BT; Young AH
    J Affect Disord; 2024 Jan; 344():284-291. PubMed ID: 37838271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.